PubMed Health⌕ Search

Biomedical subjects

L Hugonot-Diener

Publications and source records attributed to L Hugonot-Diener.

5 recordsLinked to original sources

Clinical features and assessment of severe dementia. A review.

Sound understanding of the dementia syndrome requires adequate acquaintance with its entire spectrum, from the lightest to the most advanced stages. Most studies of dementia deal with light to moderate stages of the condition, while relatively little attention has been paid to its most severe stages. This review presents a clinical description of patients with severe dementia and of the tests currently available to evaluate their cognitive, behavioural, and functional status. Available instruments such as the Hierarchic Dementia Scale or the Severe Impairment Battery now allow quantification of the cognitive and behavioural status of patients with severe dementia. Experience with severe dementia shows that, far from being in a "vegetative state", as is commonly thought, late-stage patients are in fact quite different from one another and in most cases continue to have an interaction with their environment. This ability to better define the characteristics of patients with severe dementia provides the basis for correlations between clinical data and data derived from neuroimaging, neurochemistry, or neuropathology. It also sets the stage for possible therapeutic trials involving these patients.

Alzheimer Disease↗

The Alzheimer's disease activities of daily living international scale (ADL-IS).

BACKGROUND: Activities of daily living (ADL) deficits are integral components of dementia disorders, and ADL measures are among the most robust markers of the course of Alzheimer's disease (AD). Despite this acknowledged importance, no clearly useful ADL instrument for cross-cultural application in pharmacologic trials in the early stages of AD had been available. METHOD: An international effort was launched to develop an ADL scale for pharmacologic trials in early AD. Steps taken from 1990 to the present included: (1) international scientific working group meetings and reviews, (2) reviews of existing measures, (3) collating of existent, nonredundant items, (4) querying experts for new items, (5) interviews with informants and subjects in the USA, France, and Germany, toward the identification of potential new items, (6) identification of an item pool based upon these procedures, (7) creation of a trial instrument, (8) piloting of this instrument, and (9) refinement of the scale based upon statistical analysis of the pilot data. Final item selection was based upon: (1) relevance for > or = 80% of subjects in severity-stratified USA and German samples; (2) absence of gender and national biases; (3) significant (p <.05) discrimination between (a) normal versus mildly impaired and (b) mildly impaired versus moderately to moderately severely impaired subjects; and (4) Global Deterioration Scale (GDS) scores accounting for > or = 12% of variance in the item after controlling for age and gender. RESULTS: An ADL scale consisting of 40 items that correlate with the global and cognitive progress of AD is developed for international usage in pharmacologic trials in incipient, mild, moderate, and moderately severe AD. The scale contains 40 items falling within 13 ADL categories. The 40-item scale is shown to have .81 correlation with GDS staging, .81 with mental status assessment (Mini-Mental State Examination), and .81 with a psychometric test (the SKT) (p values < .001). CONCLUSION: This scale can be used to measure therapeutic response in AD.

Activities of Daily Living↗

Lectures.

Explore the source record for details and available documents.

Journal Article↗

[Presentation by the GRECO group of the French adaptation of a cognitive assessment scale used in Alzheimer type dementia].

A consensus group on cognitive evaluation in clinical research, the GRECO, carried out a French adaptation of the American ADAS. This "unique and consensual" version answers the purposes of the original version, taking into account the constraints and customs of the French language. After presenting the ADAS-cog rating scale, the principles underlying its design, and its various items, a review of the literature is proposed. This review deals with the ADAS as a diagnosis and assessment tool to evaluate both spontaneous evolution of dementia of Alzheimer's type and drug efficacy in clinical trials.

Alzheimer Disease↗

[Out-of-hospital geriatric facilities].

In France there are many and varied housing structures for the elderly. They were created after the war in response to the progressive ageing of the population, bringing in its wake an ever increasing dependence. These structures consist of accommodation equipped for almost complete nursing care. There is a large number of such establishments situated between individual homes and long-term hospital care: homes in the form of small family type reception units (such as sheltered housing), living with a family, rest-homes and sun-homes for the least disabled. Service-flats provide a further large group of private establishments at all prices with various levels of medical care. Retirement homes with medical cures, the MAPAD, can look after the dependent chronically ill. The biggest problem concerns provision for intellectually dependent patients who are cared for in psychogeriatric units of the MAPAD or their equivalent and in structures based on very different concepts: "the cantous" or the "Jardins d'Eleusis".

Aged↗